After the release of the FDA’s Biosimilar Action Plan this week, many industry stakeholders have spoken out on the actions being taken by the FDA to further competition and increase biosimilar uptake.
After the release of the FDA’s Biosimilar Action Plan (BAP) this week, many industry stakeholders have spoken out on the actions being taken by the FDA to further competition and increase biosimilar uptake.
The plan is focused on 4 key areas; improving efficiency of biosimilar and interchangeable development and approval process, maximizing clarity for the biosimilar product development community, improving understanding of biosimilars among patients, providers and payers, and reducing gaming of FDA requirements and other attempts to unfairly delay market competition.
The Biosimilars Forum, who recently submitted comments to HHS in regard to the Trump administration’s drug pricing blueprint, commented on the release of the BAP, stating that it “marks an important step forward for cultivating a robust biosimilars market in the United States. [FDA] Commissioner Gottlieb has been a champion of biosimilars, and his plan would help support the development and approval of these innovative drugs in a number of key ways,” said the president of the Biosimilars Forum, Juliana Reed in a statement made to The Center for Biosimilars®.
In addition, Angus Worthing, MD, FACP, FACR, chair of the American College of Rheumatology (ACR) Government Affairs Committee, told the Center for Biosimilars® in an email that with the rollout of this plan, “ACR along with other doctors hopes that the pathway for interchangeable drug approval will be finalized in all due haste, to increase the number of safe and effective biosimilars in the marketplace.” ACR also submitted comments to HHS on the administration’s drug pricing plan earlier this week.
Steven Lucio, the associate vice president of pharmacy services at Vizient, said “The interchangeability of biosimilars and innovator drugs may be difficult at first, but they greatly expand opportunities for healthcare organizations to better manage pharmaceutical spending.” Vizient believes that biosimilars have the potential to significantly lower the high cost of biologic drugs, while simultaneously maintaining a high level of quality and improved clinical outcomes, he said.
Pharmaceutical companies Novartis, Roche, and Pfizer also announced their support of the BAP this week. A Novartis spokesperson remarked, “We believe in collaborative measures to ensure a fair approach to competition that enables access, reduces costs, and creates the space for continued innovation.”
In a statement, a Roche spokesperson said that the firm “looks forward” to engaging in open dialogue with the FDA to “ensure patient choice and access to the treatments they need today as well as a positive environment for scientific innovation that enables the breakthrough of medicines of the future.”
Additionally, though a Pfizer spokesperson noted that the release of the BAP is an important step in creating a robust biosimilars market within the United States, they also said that “more work needs to be done to tear down market barriers to biosimilars and it will require cooperation from a robust coalition of stakeholders, from Congress and insurers to the FDA, to biologics manufacturers, and the middle-men.”
Finally, CMS Administrator Seema Verma also had positive comments about the initiatives put forth by the FDA, and expanded on actions that CMS is undertaking to spur competition in the drug market. “CMS and FDA are both working to accelerate innovation in the biosimilars market—CMS has taken action to do so by providing biosimilars with separate payment code and by lowering the amount of cost sharing that low-income beneficiaries pay for biosimilars. We look forward to continuing to work with the FDA on the roll-out of the American Patients First blueprint.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.